Search

ReGen Factor – Metabol Boost

Future ReGen Factor products


Fibroblast Growth Factor Binding Protein 3 (FGFBP3) impacts carbohydrate and lipid metabolism



Scientific Reports volume 8, Article number: 15973 (2018)

We propose that BP3 may constitute a new therapeutic to reverse the pathology associated with metabolic syndrome that includes nonalcoholic fatty liver disease and type 2 diabetes mellitus.


Main ingredient – FGF bp3

ReGen Factor – ReGen Metabol Boost

Treatment – weight loss

Treatment – Type 2 Diabetes

Treatment – Non-alcoholic fatty liver disease.

Sep 07, 2020 (Heraldkeepers) -- Global Weight Loss and Weight Management Diet Market is valued at approximately USD 192 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 10.5% over the forecast period 2020-2027.Sep 7, 2020


Global Type 2 Diabetes Market Set to Almost Double to $58.7 Billion. The global type 2 diabetes market is set to almost double from $31.2 billion in 2015 to $58.7 billion by 2025, representing a compound annual growth rate of 6.5%, according to research and consulting firm GlobalData.

To the great surprise of cancer researchers, a protein they investigated for its possible role in cancer turned out to be a powerful regulator of metabolism. The Georgetown University-led study found that forced expression of this protein in a laboratory strain of obese mice showed a remarkable reduction of their fat mass despite a genetic predisposition to eat all the time.

The study, published in Scientific Reports, suggests that the protein FGFBP3 (BP3 for short) might offer novel therapy to reverse disorders associated with metabolic syndrome, such as type 2 diabetes and fatty liver disease.

Because BP3 is a natural protein and not an artificial drug, clinical trials of recombinant human BP3 could begin after a final round of preclinical studies, investigators say.

"We found that eight BP3 treatments over 18 days was enough to reduce the fat in obese mice by over a third," says the study's senior investigator, Anton Wellstein, MD, PhD, a professor of oncology and pharmacology at Georgetown Lombardi Comprehensive Cancer Center.

The treatments also reduced a number of obesity-related disorders in the mice, such as hyperglycemia -- excess blood sugar that is often linked to diabetes -- and eliminated the fat in their once fatty livers. Clinical as well as microscopic examination of the mice showed no side effects, researchers say.